EZH2 and prostate cancer: EZH2 activation can promote expansion of breast tumor initiating cells [30], whereas GSK126, the novel EZH2 inhibitor, exerts anticancer effects on gastric cancer and prostate cancer by inhibiting cell migration, invasion and angiogenesis [31, 32].